Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
In terms of outcomes, other adverse events (51.5%) were the most prevalent, followed by hospitalization (40.4%), life-threatening (2.8%) and death (2.7%)
The Phase 2 trial (NEJM 2023) reported an average body-weight reduction of about 24% at 48 weeks at the highest dose
Taber DJ, Meadows HB, Pilch NA, Chavin KD, Baliga PK, Egede LE
More serious side effects, such as allergic reactions, are rare but should be treated promptly if they occur
.png?w=1280&max-h=720&fit=crop&auto=format)
Further studies are required to better understand how GGT1, other GGT family members and uncharacterized proteins with GGT activity contribute to extracellular GSH catabolism
US$ 27.18
US$ 23.94
US$ 23.38
US$ 24.05
